Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 5.53
GNMK's Cash to Debt is ranked higher than
57% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 2.75 vs. GNMK: 5.53 )
Ranked among companies with meaningful Cash to Debt only.
GNMK' s Cash to Debt Range Over the Past 10 Years
Min: 5.53  Med: 1776.10 Max: No Debt
Current: 5.53
Equity to Asset 0.70
GNMK's Equity to Asset is ranked higher than
60% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. GNMK: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
GNMK' s Equity to Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.83 Max: 0.92
Current: 0.7
0.67
0.92
F-Score: 3
Z-Score: 0.01
M-Score: -2.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -115.76
GNMK's Operating margin (%) is ranked lower than
79% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. GNMK: -115.76 )
Ranked among companies with meaningful Operating margin (%) only.
GNMK' s Operating margin (%) Range Over the Past 10 Years
Min: -4488.56  Med: -476.40 Max: -106.95
Current: -115.76
-4488.56
-106.95
Net-margin (%) -116.58
GNMK's Net-margin (%) is ranked lower than
79% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. GNMK: -116.58 )
Ranked among companies with meaningful Net-margin (%) only.
GNMK' s Net-margin (%) Range Over the Past 10 Years
Min: -4383.77  Med: -478.54 Max: -107.98
Current: -116.58
-4383.77
-107.98
ROE (%) -59.79
GNMK's ROE (%) is ranked lower than
81% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. GNMK: -59.79 )
Ranked among companies with meaningful ROE (%) only.
GNMK' s ROE (%) Range Over the Past 10 Years
Min: -158.05  Med: -71.75 Max: -40.63
Current: -59.79
-158.05
-40.63
ROA (%) -47.46
GNMK's ROA (%) is ranked lower than
79% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.42 vs. GNMK: -47.46 )
Ranked among companies with meaningful ROA (%) only.
GNMK' s ROA (%) Range Over the Past 10 Years
Min: -115.7  Med: -58.79 Max: -35.46
Current: -47.46
-115.7
-35.46
ROC (Joel Greenblatt) (%) -369.59
GNMK's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. GNMK: -369.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNMK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2957.74  Med: -614.04 Max: -395.21
Current: -369.59
-2957.74
-395.21
Revenue Growth (3Y)(%) 35.10
GNMK's Revenue Growth (3Y)(%) is ranked higher than
96% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. GNMK: 35.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNMK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.3  Med: 39.65 Max: 52.5
Current: 35.1
-22.3
52.5
EBITDA Growth (3Y)(%) -13.80
GNMK's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. GNMK: -13.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GNMK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.4  Med: -31.70 Max: -13.8
Current: -13.8
-63.4
-13.8
EPS Growth (3Y)(%) -13.80
GNMK's EPS Growth (3Y)(%) is ranked lower than
73% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. GNMK: -13.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GNMK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.8  Med: -31.30 Max: -13.8
Current: -13.8
-62.8
-13.8
» GNMK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNMK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about GenMark Diagnostics Inc

Weekly CFO Buys Highlight: Twitter, GenMark Diagnostics, FireEye Recent insider buys
According to GuruFocus Insider Data, the recent CFO buys were: Twitter Inc. (NYSE:TWTR), GenMark Diagnostics Inc. (NASDAQ:GNMK) and FireEye Inc. (NASDAQ:FEYE). Read more...

Ratios

vs
industry
vs
history
P/B 3.94
GNMK's P/B is ranked lower than
73% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. GNMK: 3.94 )
Ranked among companies with meaningful P/B only.
GNMK' s P/B Range Over the Past 10 Years
Min: 1.61  Med: 4.55 Max: 10.43
Current: 3.94
1.61
10.43
P/S 5.91
GNMK's P/S is ranked lower than
91% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. GNMK: 5.91 )
Ranked among companies with meaningful P/S only.
GNMK' s P/S Range Over the Past 10 Years
Min: 5.92  Med: 15.00 Max: 24.96
Current: 5.91
5.92
24.96
Current Ratio 5.41
GNMK's Current Ratio is ranked higher than
78% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.82 vs. GNMK: 5.41 )
Ranked among companies with meaningful Current Ratio only.
GNMK' s Current Ratio Range Over the Past 10 Years
Min: 3.19  Med: 6.84 Max: 14.02
Current: 5.41
3.19
14.02
Quick Ratio 5.18
GNMK's Quick Ratio is ranked higher than
82% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. GNMK: 5.18 )
Ranked among companies with meaningful Quick Ratio only.
GNMK' s Quick Ratio Range Over the Past 10 Years
Min: 3.15  Med: 6.60 Max: 13.78
Current: 5.18
3.15
13.78
Days Inventory 53.01
GNMK's Days Inventory is ranked higher than
86% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. GNMK: 53.01 )
Ranked among companies with meaningful Days Inventory only.
GNMK' s Days Inventory Range Over the Past 10 Years
Min: 47.43  Med: 62.09 Max: 90.13
Current: 53.01
47.43
90.13
Days Sales Outstanding 43.86
GNMK's Days Sales Outstanding is ranked higher than
84% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 69.24 vs. GNMK: 43.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNMK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.08  Med: 62.17 Max: 96.52
Current: 43.86
38.08
96.52
Days Payable 123.54
GNMK's Days Payable is ranked higher than
78% of the 255 Companies
in the Global Medical Devices industry.

( Industry Median: 60.71 vs. GNMK: 123.54 )
Ranked among companies with meaningful Days Payable only.
GNMK' s Days Payable Range Over the Past 10 Years
Min: 70.64  Med: 90.56 Max: 266.25
Current: 123.54
70.64
266.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.86
GNMK's Price/Net Cash is ranked higher than
72% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 12.77 vs. GNMK: 6.86 )
Ranked among companies with meaningful Price/Net Cash only.
GNMK' s Price/Net Cash Range Over the Past 10 Years
Min: 1.98  Med: 5.33 Max: 13.27
Current: 6.86
1.98
13.27
Price/Net Current Asset Value 5.46
GNMK's Price/Net Current Asset Value is ranked higher than
55% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 6.17 vs. GNMK: 5.46 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNMK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.82  Med: 4.99 Max: 9.94
Current: 5.46
1.82
9.94
Price/Tangible Book 4.16
GNMK's Price/Tangible Book is ranked higher than
51% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. GNMK: 4.16 )
Ranked among companies with meaningful Price/Tangible Book only.
GNMK' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.64  Med: 4.46 Max: 8.34
Current: 4.16
1.64
8.34
Price/Median PS Value 0.39
GNMK's Price/Median PS Value is ranked higher than
91% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. GNMK: 0.39 )
Ranked among companies with meaningful Price/Median PS Value only.
GNMK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.61  Med: 0.97 Max: 1.56
Current: 0.39
0.61
1.56
Earnings Yield (Greenblatt) (%) -24.16
GNMK's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. GNMK: -24.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNMK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -24.16  Med: 0.00 Max: 0
Current: -24.16
-24.16
0

More Statistics

Revenue(Mil) $36
EPS $ -1.01
Beta0.54
Short Percentage of Float21.89%
52-Week Range $4.63 - 14.11
Shares Outstanding(Mil)42.44

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 38 53 66
EPS($) -1.10 -1.26 -1.09
EPS without NRI($) -1.10 -1.26 -1.09

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:GNF.Germany,
GenMark Diagnostics Inc was incorporated in the State of Delaware in February 2010. The Company is a molecular diagnostics company developing and commercializing its proprietary eSensor detection technology. Its proprietary electrochemical technology enables fast, accurate and highly sensitive detection of up to 72 distinct biomarkers in a single sample. The Company's XT-8 System received 510(k) clearance from the Food and Drug Administration and is designed to support molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified nucleic acid sample, its XT-8 system produces clear results. The Company's XT-8 System supports up to 24 test cartridges, of which each could be run independently, resulting in a highly convenient and flexible workflow for its customers, which are hospitals and reference laboratories. It intends to expand the use of its XT-8 System and diagnostic tests to those reference laboratories and hospitals in the United States which perform a high volume of molecular diagnostic tests. The Company's XT-8 System is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform fast, accurate and easy-to-use molecular diagnostic tests. The XT-8 System, which employs its proprietary electrochemical detection technology, consists of a compact bench-top workstation with an integrated touch screen computer and an analyzer into which the self-contained, disposable test cartridges are inserted. The Company's proprietary eSensor technology is based on the competitive DNA hybridization and electrochemical detection. The Company's test cartridges are self-contained devices specifically programmed and configured for a given diagnostic test. Each test cartridge includes a sample compartment and a plastic cover that forms a hybridization chamber. The Company's XT-8 instrument is a multiplex workstation that has a modular design consisting of a base module and up to three test cartridge-processing towers of eight cartridge slots each. It faces competition in the molecular diagnostic testing markets with testing products and systems developed by public and private companies such as Cepheid, Gen-Probe, Inc., Siemens, Hologic, Inc., Innogenetics, Inc, Luminex Corporation, Nanosphere, Inc., Qiagen NV, Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., Idaho Technologies and Abbott Diagnostics, a division of Abbott Laboratories. The Company's diagnostic tests also face competition with the LDTs developed by national and regional reference laboratories and hospitals. The design, development, manufacture, testing and sale of its diagnostic products are subject to regulation by numerous governmental authorities, the FDA, and corresponding state and foreign regulatory agencies.
» More Articles for GNMK

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: Twitter, GenMark Diagnostics, FireEye Nov 09 2015 
Weekly CFO Buys Highlight: SunEdison Inc, Genpact Ltd, GenMark Diagnostics Inc. Aug 31 2015 
Weekly CFO Buys Highlight: XPL, GNMK Jul 02 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 03 2016
GenMark Announces Preliminary Q4 Financial Results and Initiation of ePlex™ Analytical Studies Jan 12 2016
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 12 2016
GenMark Announces Preliminary Q4 Financial Results and Initiation of ePlex™ Analytical Studies Jan 12 2016
GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : January 7, 2016 Jan 07 2016
GenMark Diagnostics to Present at the 2016 J.P. Morgan Healthcare Conference Dec 30 2015
GenMark Diagnostics to Present at the 2016 J.P. Morgan Healthcare Conference Dec 30 2015
Healthcare Sector Equities in Motion -- Tetraphase Pharma, Cardiovascular Systems, Sagent Pharma,... Dec 21 2015
GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : December 14, 2015 Dec 14 2015
GENMARK DIAGNOSTICS, INC. Financials Dec 08 2015
GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : December 1, 2015 Dec 01 2015
Can The Uptrend Continue for GenMark (GNMK)? Dec 01 2015
Do Hedge Funds Love Paratek Pharmaceuticals Inc (PRTK)? Nov 25 2015
Weekly CFO Buys Highlight: Twitter, GenMark Diagnostics, FireEye Nov 09 2015
Why Three Biotech Stocks Are Getting Pounded Alongside A Financial Stock Today Oct 28 2015
Edited Transcript of GNMK earnings conference call or presentation 27-Oct-15 8:30pm GMT Oct 27 2015
GenMark Diagnostics reports 3Q loss Oct 27 2015
GenMark Diagnostics reports 3Q loss Oct 27 2015
GenMark Diagnostics Inc Earnings Call scheduled for 4:30 pm ET today Oct 27 2015
GenMark Diagnostics Reports Q3 Financial Results Oct 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK